A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 28,548 shares of SAGE stock, worth $155,301. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,548
Previous 29,418 2.96%
Holding current value
$155,301
Previous $319,000 35.42%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 28, 2024

SELL
$7.02 - $13.08 $6,107 - $11,379
-870 Reduced 2.96%
28,548 $206,000
Q2 2024

Jul 26, 2024

SELL
$10.58 - $17.9 $20,493 - $34,672
-1,937 Reduced 6.18%
29,418 $319,000
Q1 2024

Apr 24, 2024

SELL
$18.62 - $26.95 $35,713 - $51,690
-1,918 Reduced 5.76%
31,355 $588,000
Q4 2023

Feb 09, 2024

SELL
$17.1 - $22.26 $30,780 - $40,068
-1,800 Reduced 5.13%
33,273 $721,000
Q3 2023

Oct 24, 2023

SELL
$16.75 - $48.98 $8,375 - $24,490
-500 Reduced 1.41%
35,073 $722,000
Q2 2023

Jul 13, 2023

SELL
$40.65 - $59.54 $27,072 - $39,653
-666 Reduced 1.84%
35,573 $1.67 Million
Q1 2023

May 11, 2023

SELL
$37.27 - $46.57 $7,155 - $8,941
-192 Reduced 0.53%
36,239 $1.52 Million
Q4 2022

Feb 08, 2023

BUY
$32.2 - $43.61 $1.17 Million - $1.59 Million
36,431 New
36,431 $1.39 Million
Q1 2020

May 08, 2020

SELL
$26.15 - $77.24 $90,923 - $268,563
-3,477 Closed
0 $0
Q4 2019

Feb 04, 2020

BUY
$60.18 - $154.77 $70,290 - $180,771
1,168 Added 50.58%
3,477 $251,000
Q3 2019

Nov 06, 2019

BUY
$140.29 - $189.96 $38,439 - $52,049
274 Added 13.46%
2,309 $323,000
Q2 2019

Aug 15, 2019

BUY
$157.85 - $183.09 $321,224 - $372,588
2,035 New
2,035 $0

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $323M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.